VIDEO: Syfovre shows continued efficacy in GA lesion growth reduction in extension study
Click Here to Manage Email Alerts
SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Charles C. Wykoff, MD, PhD, discusses data from the GALE long-term extension study investigating Apellis Pharmaceuticals’ Syfovre for geographic atrophy.
At 36 months of continuous pegcetacoplan dosing, Syfovre (pegcetacoplan injection) reduced GA lesion growth by up to 35% when dosed monthly and by approximately 24% when dosed every other month. In addition, patients with foveal sparing at baseline saw up to 42% growth reduction when treated monthly, Wykoff said.
Wykoff also discussed the study’s safety findings, which were consistent with previously reported phase 3 data from the OAKS and DERBY trials.
“The rare events of vasculitis and severe vision loss in the real world have not been seen in the clinical trial to date,” he said.
Collapse
Wykoff C. Long-term efficacy and safety of pegcetacoplan from the GALE open-label extension of the phase 3 OAKS and DERBY trials. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Read more about
Click Here to Manage Email Alerts